News
12-11-2013, 12:00 AM
NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced nationwide availability of the Prosigna™ Breast Cancer Prognostic Gene Signature Assay beginning in the first quarter of 2014.
More... (http://www.news-medical.net/news/20131211/Nanostring-Technologies-announces-nationwide-availability-of-Prosigna-Breast-Cancer-Assay-in-2014.aspx)
More... (http://www.news-medical.net/news/20131211/Nanostring-Technologies-announces-nationwide-availability-of-Prosigna-Breast-Cancer-Assay-in-2014.aspx)